These criteria are applied to pre-operative imaging +/- serum alpha-fetoprotein (AFP) levels to determine LT eligibility and may differ from the eventual explant pathology (i.e., underestimate tumor stage) in 15-30% of patients (5, 6). The gene discussed is AFP; the disease is neoplasm.